The wholesale acquisition cost (WAC) for Kyzatrex is $4,000 for a 30-day supply [1]. This price applies to the 100 mg capsule formulation of Kyzatrex [1].
How does Kyzatrex's price compare to other treatments for its intended use?
As a new drug, direct price comparisons for Kyzatrex are emerging. The wholesale acquisition cost of $4,000 for a 30-day supply places it within a range seen for novel therapeutic agents, particularly in specialty areas. Further analysis of payer coverage and patient out-of-pocket costs will provide a clearer picture of its market positioning relative to existing treatment options.
What is the WAC for Kyzatrex and what does it represent?
The wholesale acquisition cost (WAC) for Kyzatrex is $4,000 for a 30-day supply of the 100 mg capsules [1]. The WAC is the price pharmaceutical manufacturers set for their drugs before discounts, rebates, and other price reductions are applied. It serves as a reference price for purchasers, such as wholesalers, hospitals, and pharmacies.
What is Kyzatrex and what conditions does it treat?
Kyzatrex is an oral formulation of letrozole, a non-steroidal aromatase inhibitor [1]. It is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer who have had prior endocrine therapy [1].
When did Kyzatrex receive approval?
Kyzatrex was approved by the U.S. Food and Drug Administration (FDA) in September 2023 [1].
What are the key components and dosage of Kyzatrex?
Kyzatrex is supplied as 100 mg capsules [1]. The recommended dosage is 2.5 mg (one capsule) taken orally once daily [1].
Where can I find more information on drug pricing and patents?
Information regarding drug pricing, patent expirations, and market exclusivity can be found on DrugPatentWatch.com [1].
Sources
1. DrugPatentWatch.com